Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said
You may also be interested in...
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
"Black Box" Will Not Deter Off-Label Zyprexa Use In Dementia Patients, Lilly Says
The company points to the lack of indicated alternatives for treating dementia-related psychosis as one reason why psychiatrists will continue to prescribe atypical antipsychotics despite a new "black box" warning on mortality in that patient population. First quarter U.S. Zyprexa sales fell 17% compared to the same period in 2004.